doi: 10.1177/2040622315609312 59 ChristensenMKnopFKHolstJJVilsbollT
Medications used to treat diabetes and obesity might also help people struggling with substance use disorder (SUD)
The downstream health savings from that magnitude of weight loss include: | Potential Savings | Annual Value | |-------------------|-------------| | Reduced diabetes risk/medications -- see [GLP-1 comparison chart](/guides/glp1-medications-comparison-chart-guide) for all options | $2,000-6,000 | | Blood pressure medication reduction | $600-1,800 | | Sleep apnea treatment reduction | $1,200-3,600 | | Avoided bariatric surgery | $20,000-35,000 (one-time) | | Reduced joint replacement risk | $30,000-50,000 (lifetime) | Against a first-year cost of $3,000-5,500 for compounded retatrutide, the financial case is strong for patients who respond well
Puede sentir el dolor desde el abdomen hasta la espalda
These medications help: Slow stomach emptying, leading to increased feelings of fullness Reduce appetite and food intake by acting on brain centers that control hunger Improve insulin secretion and sensitivity Lower blood sugar levels, especially after meals Promote weight loss through multiple mechanisms Mounjaro (tirzepatide) is actually a dual GIP/GLP-1 receptor agonist, meaning it acts on two hormonal pathways related to blood sugar control and appetite regulation, which may explain its particularly strong effects on weight loss
